Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Nitroscanate
The Bob Martin Company
QP52AX01
Nitroscanate
500 mg/tablet
Coated tablet
CAM: Companion Animal Medicine as defined in relevant national legislation
Dogs
nitroscanate
Endoparasiticide
Authorised
1995-07-10
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Bob Martin Clear Wormer 500 mg Film Coated Tablets for Dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated Tablet. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES The product is a broad spectrum anthelmintic for use in puppies and adult dogs for the treatment of infection by adult intestinal nematodes or cestodes of the following species: Nematodes: _Toxocara caninum, Toxascaris leonina, Ancylostoma caninum, Uncinaria stenocephala_ Cestodes: _Taenia hydatigena, Taenia pisiformis_, and_ Dipylidium caninum_. 4.3 CONTRAINDICATIONS Do not administer to sick or convalescing animals. Do not use in puppies of less than 3 weeks of age. Do not use in cases of hepatic dysfunction. Do not use in cases of known hypersensitivity to the active substance. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The product is not indicated for the treatment of_ Trichuris vulpis_ and gives only a limited level of control of _Echinococcus granulosus._ Since the most common tapeworm of the dog (_Dipylidium caninum_) is transmitted by a flea and has a very short pre- patent period, it is important to pay attention to flea control to reduce the incidence of tapeworm in your pet. Each tablet contains: ACTIVE SUBSTANCE; QUANTITY: Nitroscanate 500 mg H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _1_ _9_ _/_ Read the complete document